Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled Dysport trial for neurogenic detrusor overactivity urinary incontinence
MOH_2017-03-14_000215Phase 3Recruiting
- Sponsor
- Ipsen Innovation
- Start
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in detrusor hyperreflexia (DH) and urinary incontinence (UI) (3 arms), sponsored by Ipsen Innovation. Primary endpoint: Change in urinary incontinence from baseline to Week 6 after first study treatment. Started May 2016; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)
Beyond the preview
Go deeper on MOH_2017-03-14_000215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000215.